Papers
8
Total Citations
285
H-Index
7
About
Dr. Boris Sepesi is a leading thoracic surgeon whose research lies at the intersection of advanced surgical techniques and cutting-edge immunotherapy for non-small cell lung cancer (NSCLC). He is best known for his pivotal role in the NEOSTAR study, which demonstrated the safety and efficacy of neoadjuvant nivolumab, alone or with ipilimumab, before surgical resection—a paradigm-shifting approach that has garnered over 140 citations across related publications. Dr. Sepesi has also been instrumental in advancing robotic-assisted lobectomy and segmentectomy, with his comprehensive institutional experience (92 citations) helping to establish minimally invasive surgery as a standard for NSCLC. Beyond oncology, his work on opioid stewardship in thoracic surgery, including a landmark study showing sustained reductions in discharge prescriptions through enhanced recovery programs, has influenced perioperative care protocols. With a career marked by high-impact clinical trials and a commitment to optimizing both oncologic and surgical outcomes, Dr. Sepesi’s contributions are shaping the future of lung cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8